Mahsa Ghajarzadeh; Hassan Seirafi; Hossein Alinia; Kamran Balighi; Hossein Mortazavi; Maryam Akhyani
Volume 14, Issue 4 , 2011, , Pages 129-130
Abstract
Vitiligo is an autoimmune skin disease which is characterized by depigmented patches due to loss of pigment cells. Evidence suggests that cell-mediated immunity plays a role in melanocyte destruction while some patients have antibodies to melanocytes or melanocytic proteins. Vitiligo is strongly associated ...
Read More
Vitiligo is an autoimmune skin disease which is characterized by depigmented patches due to loss of pigment cells. Evidence suggests that cell-mediated immunity plays a role in melanocyte destruction while some patients have antibodies to melanocytes or melanocytic proteins. Vitiligo is strongly associated with a number of autoimmune disorders. Autoimmune thyroiditis is the most prevalent disease with a prevalence of 21%1. Diabetes mellitus type I is found in 1-7% of the patients with vitiligo 2 and pernicious anemia is reported in 5% of the vitiligo patients 3. The goal of this study was to determine the association of vitiligo with other autoimmune diseases (diabetes, thyroid dysfunction, pernicious anemia) in Iranian patients. From January 2009 until January 2010, one hundred vitiligo patients were randomly selected (through simple random selection) from the outpatient clinic of Razi Hospital.
Maryam Akhyani; Hasan Seirafi; Zahra Hallaji; Pardis Kiani; Sara Sabouri rad; Hosein Ahrar Mohammad
Volume 14, Issue 1 , 2011, , Pages 6-11
Abstract
Background: Alopecia Areata (AA) is a recurrent non-scarring type of hair loss that can affect any hair-bearing area. Prognosis of AA is unpredictable and most patients experience more than one episode of hair loss. The purpose of this study was to investigate the relationship between the severity of ...
Read More
Background: Alopecia Areata (AA) is a recurrent non-scarring type of hair loss that can affect any hair-bearing area. Prognosis of AA is unpredictable and most patients experience more than one episode of hair loss. The purpose of this study was to investigate the relationship between the severity of AA with respect to age of onset, nail involvement, family history, number of recurrences and duration of the disease. Methods: A total of 239 consecutive patients with AA who were visited in our dermatology clinic from June 2009 to November 2009 were included in this study. The extent of scalp involvement, age of onset, nail involvement, family history, number of recurrences and duration of AA were recorded. Results: Two hundred and thirty nine (239) patients with AA including 141 males and 98 females entered our analysis (male: female ratio = 1.43:1). The age of the patients at the onset of the disease had a wide range from 1 to 60 years (mean ± SD = 21.51 ± 5.4). Two hundred and twelve patients (88.7%) had their first episode of AA before the age of 40 years. Duration of the AA varied from 1 month to 31 years. Ninety six (40.2%) patients experienced only one episode and 25 patients (10.5%) had more than 4 episode of alopecia. Nail changes was reported in 34 patients (14.2%). Forty five patients (18.8%) had a positive family history of alopecia areata. A personal history of atopy and autoimmune diseases was seen in 23 (9.6%) and 27 (11.3%) patients, respectively. The relationship between extensive AA and age of onset, duration, nail changes and positive family history was confirmed (p 0.05). Conclusion: AA occurred at a comparatively younger age. There was a correlation between extensive alopecia areata and age of onset, duration, nail changes, and positive family history as prognostic factors. There were no relationships between the severity of AA and sex, history of atopy and autoimmune diseases.
